Snowball logo
logo
PBIG_logo

Paradigm Biopharmaceuticals Limited

PBIGF • PINK
$0.0119$0.00  (0%)
Estimate
EPS
-0.1
Beta
0.027
Growth
Revenue, YoY
557.75%
Net income, YoY
-1,015.47%
About the company
Ticker
PBIGF
ISIN
Country
Australia
Sector (GICS)
Healthcare
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Frequently asked questions

What sector does Paradigm Biopharmaceuticals Limited (PBIGF) operate in?

Paradigm Biopharmaceuticals Limited belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Paradigm Biopharmaceuticals Limited (PBIGF) current stock price?

As of the latest data, Paradigm Biopharmaceuticals Limited stock price is $0.01, with a previous close of $0.01.

What is Paradigm Biopharmaceuticals Limited (PBIGF) current market capitalization?

Paradigm Biopharmaceuticals Limited market cap is approximately 7.45 million.

What is Paradigm Biopharmaceuticals Limited (PBIGF) Earnings Per Share (EPS)?

The trailing EPS is -$0.10.

What is Paradigm Biopharmaceuticals Limited (PBIGF) EBITDA?

Paradigm Biopharmaceuticals Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -39.15 million.

Does Paradigm Biopharmaceuticals Limited (PBIGF) pay dividends?

No. Paradigm Biopharmaceuticals Limited does not pay a dividend.

What is Paradigm Biopharmaceuticals Limited (PBIGF) beta (volatility) score?

Paradigm Biopharmaceuticals Limited has a beta of 0.027, indicating lower volatility than the overall market.